Opinion|Videos|October 25, 2024
Therapies Beyond the Front Line for SCLC
Key Takeaways
- Tarlatamab is a newly approved therapy, marking progress beyond first-line treatments for SCLC.
- Researchers are exploring novel agents and combination therapies to enhance patient outcomes in SCLC.
Panelists discuss how treatment options for small cell lung cancer (SCLC) extend beyond first-line therapies and the recently approved tarlatamab, exploring existing treatments in the second-line and beyond while also highlighting promising ongoing clinical trials and emerging therapies that show potential for improving outcomes in SCLC patients.
Advertisement
Episodes in this series
We’ve discussed first-line therapies and a newly approved therapy tarlatamab.
- Beyond first-line therapies, what options exist for patients, and what clinical trials are you excited about?
- What are some of the therapies being researched for small cell lung cancer (SCLC) that you are excited about?
How do you see the management of SCLC evolving in the future?
Advertisement
Related to this article
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.
Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
3
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5